by Stacey Johnson | Dec 27, 2013
If you are fortunate enough to have time off over the holiday season, I’ll wager that you may spend some of that time in front of the television. Call me a Grinch, but Christmas TV programming is something that I generally avoid. If, like me, you plan on...
by Angela C. H. McDonald | Dec 23, 2013
> Last Friday afternoon, I raced over to a University of Toronto neighbourhood pub for the annual Ontario Stem Cell Initiative (OSCI) holiday party. This year, OSCI decided to change up the usual scientific poster session and created a science communication...
by Stacey Johnson | Dec 20, 2013
. With five days left to go until Christmas, are you feeling stressed about that hard-to-buy-for person on your Christmas list? Don’t despair. I have scoured the Internet on your behalf and found the perfect gift for the scientist in your life or the person who loves...
by Paul Krzyzanowski | Dec 16, 2013
> This is part three of an interview series with Michael West, CEO of BioTime. Read parts one and two. The prospects for BioTime and other companies that operate in the tissue engineering and cell therapy market are good. The industry is growing by about 18% per...
by Patrick Blit | Dec 13, 2013
. Regenerative architecture is an architectural discipline that explores the use of novel designs for the goal of producing sustainable structures that minimize the impact on our planet. You’re probably thinking that bamboo flooring is an example of this and you...
by Natasha Davie | Dec 10, 2013
. The UK has previously committed to incorporating some sort of value based pricing into its reimbursement scheme to improve patient access to innovative medicines. With recent backtracking on this decision, as the Jan 2014 deadline for this integration approaches, we...
by Lisa Willemse | Dec 6, 2013
> To be, or not to be, that is the question: Whether ’tis Nobler in the mind to suffer The Slings and Arrows of outrageous Fortune, Or to take Arms against a Sea of troubles, And by opposing end them We know this famous soliloquy from Shakespeare’s...
by Lisa Willemse | Dec 6, 2013
> I’ve been thinking a lot about cancer lately: the mother of a good friend of mine is in the last stages of a terminal battle with pancreatic cancer and my godfather, a man with whom I share fond memories of practical jokes and summer farm vacations, was...
by Ben Paylor | Dec 5, 2013
> Just over two years ago I wrote about early reports from Dr. Roberto Bolli et al.’s SCIPIO trial running out of the University of Louisville in collaboration with the Harvard Medical School. Since this time, much has happened in the realm of cell therapy to treat...
by Nick Dragojlovic | Dec 2, 2013
> As the expiration of the California Institute for Regenerative Medicine’s (CIRM) funding approaches, the fate of CIRM after 2017 is top of mind for stem cell researchers in the state. While the agency’s leadership appears to be leaning towards some form of...
Comments